A comprehensive telehealth company that is gaining market share and achieving EBITDA profitability. With new access to Novo's GLP-1 (like HIMS), they stand poised to accelerate business trends further. Short interest is high as we sit at all-time highs, a potentially potent recipe for this current market environment.
Guggenheim starts Personalis with a Buy, cites 'best-in-class infrastructure' As previously reported, Guggenheim initiated coverage of Personalis with a Buy rating and $6 price target. Personalis has built a best-in-class infrastructure to do comprehensive genomic, proteomic, and immune profiling in tissue and blood for therapy selection and MRD, says the analyst. While "the dreams of becoming a Porsche have faded far into the rearview mirror," management has reduced risk and is innovative in responsible revenue generation, adds the analyst, who views the company's products as "having a place on the market."
Hi Saleem,
ReplyDeleteGreat UBER trade - good luck with next!
Stocktrader
Hi Saleem,
ReplyDeleteNew pick: LFMD
A comprehensive telehealth company that is gaining market share and achieving EBITDA profitability. With new access to Novo's GLP-1 (like HIMS), they stand poised to accelerate business trends further. Short interest is high as we sit at all-time highs, a potentially potent recipe for this current market environment.
Stocktrader
Hi Saleem,
ReplyDeleteNew note on a portfolio company:
Guggenheim starts Personalis with a Buy, cites 'best-in-class infrastructure'
As previously reported, Guggenheim initiated coverage of Personalis with a Buy rating and $6 price target. Personalis has built a best-in-class infrastructure to do comprehensive genomic, proteomic, and immune profiling in tissue and blood for therapy selection and MRD, says the analyst. While "the dreams of becoming a Porsche have faded far into the rearview mirror," management has reduced risk and is innovative in responsible revenue generation, adds the analyst, who views the company's products as "having a place on the market."
Stocktrader
Hi Stocktrader,
ReplyDeleteThanks for your ongoing research with your recommendations which is much appreciated by BLOG visitors.
Saleem